CN115697328A - 抗病毒化合物及其给药方法 - Google Patents

抗病毒化合物及其给药方法 Download PDF

Info

Publication number
CN115697328A
CN115697328A CN202180021244.6A CN202180021244A CN115697328A CN 115697328 A CN115697328 A CN 115697328A CN 202180021244 A CN202180021244 A CN 202180021244A CN 115697328 A CN115697328 A CN 115697328A
Authority
CN
China
Prior art keywords
body weight
weight per
per dose
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021244.6A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·M.H.·格雷格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202511049799.8A priority Critical patent/CN120754260A/zh
Publication of CN115697328A publication Critical patent/CN115697328A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202180021244.6A 2020-03-23 2021-03-23 抗病毒化合物及其给药方法 Pending CN115697328A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511049799.8A CN120754260A (zh) 2020-03-23 2021-03-23 抗病毒化合物及其给药方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993121P 2020-03-23 2020-03-23
US62/993,121 2020-03-23
PCT/US2021/070300 WO2021195661A1 (en) 2020-03-23 2021-03-23 Anti-viral compounds and methods for administration thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511049799.8A Division CN120754260A (zh) 2020-03-23 2021-03-23 抗病毒化合物及其给药方法

Publications (1)

Publication Number Publication Date
CN115697328A true CN115697328A (zh) 2023-02-03

Family

ID=77890599

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180021244.6A Pending CN115697328A (zh) 2020-03-23 2021-03-23 抗病毒化合物及其给药方法
CN202511049799.8A Pending CN120754260A (zh) 2020-03-23 2021-03-23 抗病毒化合物及其给药方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511049799.8A Pending CN120754260A (zh) 2020-03-23 2021-03-23 抗病毒化合物及其给药方法

Country Status (19)

Country Link
US (2) US20230263778A1 (https=)
EP (2) EP4110330A4 (https=)
JP (2) JP2023519158A (https=)
KR (2) KR20250126146A (https=)
CN (2) CN115697328A (https=)
AU (2) AU2021244718A1 (https=)
BR (1) BR112022018236A2 (https=)
CA (2) CA3170367A1 (https=)
CL (1) CL2022002481A1 (https=)
CO (1) CO2022014073A2 (https=)
CR (1) CR20220491A (https=)
DO (1) DOP2022000185A (https=)
EC (1) ECSP22076862A (https=)
IL (2) IL296152A (https=)
MX (2) MX2022011370A (https=)
PE (1) PE20221868A1 (https=)
PH (1) PH12022552324A1 (https=)
WO (1) WO2021195661A1 (https=)
ZA (1) ZA202211060B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021195661A1 (en) * 2020-03-23 2021-09-30 Gregg John M H Anti-viral compounds and methods for administration thereof
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2023075714A1 (en) * 2021-10-25 2023-05-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder compositions comprising anti-viral agents
IT202100029909A1 (it) * 2021-11-26 2023-05-26 Craniomed Group S R L Combinazione di uno o più antibiotici della classe delle ansamicine con uno o più altri antibiotici per la prevenzione e il trattamento di infezioni causate da coronavirus, delle relative malattie e degli effetti clinici indotti dalle tossine prodotte a seguito dell’infezione da coronavirus.
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
KR20260016489A (ko) * 2023-05-30 2026-02-03 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제를 제조하는 피릴륨 방법
CN120983460A (zh) * 2025-09-25 2025-11-21 中国农业科学院饲料研究所 泰乐菌素衍生物在制备抗痘病毒科病毒药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20040180036A1 (en) * 2003-01-21 2004-09-16 Control Delivery Systems, Inc. Salts of codrugs and uses related thereto
US20050164994A1 (en) * 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
WO2005113580A1 (en) * 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
US20070112050A1 (en) * 2005-04-12 2007-05-17 Psivida Inc. HMGCoA reductase inhibitor combinations and uses thereof
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
WO2008094507A2 (en) * 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
CN111450088A (zh) * 2020-04-30 2020-07-28 上海爱启医药技术有限公司 二杨梅素基二硒醚的药物应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326763A1 (en) * 1998-04-30 1999-11-11 Theodore O. Johnson, Jr. Antipicornaviral compounds and compositions, their pharmaceutical uses, and methods for their synthesis
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
US20170044096A1 (en) * 2013-03-15 2017-02-16 Rutgers, The State University Of New Jersey Augmenting Moieties for Anti-Inflammatory Compounds
WO2015051268A2 (en) * 2013-10-04 2015-04-09 The Johns Hopkins University Hiv protease inhibitors against picornavirus infection
DK3785717T3 (da) * 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
EP3863453A4 (en) * 2018-10-18 2022-11-23 Qnovia, Inc. ELECTRONIC DEVICE FOR GENERATION OF AN AEROSOL FOR INHALATION BY A PERSON
US20230157998A1 (en) * 2020-03-06 2023-05-25 Pfizer Inc. Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
WO2021194927A1 (en) * 2020-03-22 2021-09-30 Tlc Biopharmaceuticals, Inc. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
WO2021195661A1 (en) * 2020-03-23 2021-09-30 Gregg John M H Anti-viral compounds and methods for administration thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20050164994A1 (en) * 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
US20040180036A1 (en) * 2003-01-21 2004-09-16 Control Delivery Systems, Inc. Salts of codrugs and uses related thereto
WO2005113580A1 (en) * 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20070112050A1 (en) * 2005-04-12 2007-05-17 Psivida Inc. HMGCoA reductase inhibitor combinations and uses thereof
WO2008094507A2 (en) * 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
CN111450088A (zh) * 2020-04-30 2020-07-28 上海爱启医药技术有限公司 二杨梅素基二硒醚的药物应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Guidelines for the treatment of people with COVI-19 disease Edition 2.0, 13 March 2020", pages 1 - 13, Retrieved from the Internet <URL:https://www.acep.org/siteassets/images/italian-guidelines-for-covid-19-google-translate.pdf.pdf> *
HAI XU等: "Flavones inhibit the hexameric replicative helicase RepA", 《NUCLEIC ACIDS RESEARCH》, vol. 29, no. 24, pages 5058 - 5066 *
JIA LIU等: "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro", 《CELL DISCOVERY》, vol. 6, no. 16, pages 1 - 4 *
MANLI WANG等: "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", 《CELL RES.》, vol. 30, no. 3, pages 269 - 271, XP037049320, DOI: 10.1038/s41422-020-0282-0 *
N. DAS等: "Codrug: An efficient approach for drug optimization", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 41, 1 October 2010 (2010-10-01), pages 571 - 588, XP027493532, DOI: 10.1016/j.ejps.2010.09.014 *
TIMOTHY P. SHEAHAN等: "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV", 《NATURE COMMUNICATIONS》, vol. 11, pages 1 - 14, XP055805666, DOI: 10.1038/s41467-019-13940-6 *
YAN ZHONG等: "Synthesis, stability and pharmacological evaluation of a novel codrug consisting of lamivudine and ursolic acid", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 45, 9 November 2011 (2011-11-09), pages 110 - 115, XP028341135, DOI: 10.1016/j.ejps.2011.10.028 *
搜狐网，哈尔滨医科大学: "新冠肺炎药物指导手册（二）糖皮质激素", pages 2, Retrieved from the Internet <URL:https://www.sohu.com/a/377401366_10009298> *

Also Published As

Publication number Publication date
JP2023519158A (ja) 2023-05-10
IL323820A (en) 2025-12-01
CA3170367A1 (en) 2021-09-30
EP4110330A1 (en) 2023-01-04
MX2025008873A (es) 2025-09-02
JP2025166040A (ja) 2025-11-05
AU2021244718A1 (en) 2022-11-03
AU2025217394A1 (en) 2025-09-04
CN120754260A (zh) 2025-10-10
US20230201167A1 (en) 2023-06-29
IL296152A (en) 2022-11-01
ECSP22076862A (es) 2022-11-30
MX2022011370A (es) 2022-10-07
PE20221868A1 (es) 2022-12-02
US20230263778A1 (en) 2023-08-24
WO2021195661A1 (en) 2021-09-30
BR112022018236A2 (pt) 2022-10-25
EP4628100A2 (en) 2025-10-08
CL2022002481A1 (es) 2023-02-10
CA3280568A1 (en) 2025-10-28
EP4110330A4 (en) 2024-04-03
KR20250126146A (ko) 2025-08-22
ZA202211060B (en) 2023-12-20
KR20220158242A (ko) 2022-11-30
PH12022552324A1 (en) 2023-12-04
CO2022014073A2 (es) 2022-10-31
CR20220491A (es) 2022-12-12
DOP2022000185A (es) 2023-01-31
US12285413B2 (en) 2025-04-29
EP4628100A3 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
CN115697328A (zh) 抗病毒化合物及其给药方法
AU2006214166B2 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
AU2018330329B2 (en) Methods of using dipivefrin
US20210330635A1 (en) Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
EA052657B1 (ru) Противовирусные соединения и способы их применения
US20250057803A1 (en) Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection
TW202440070A (zh) 用於治療、改善或預防病毒感染的製品及治療組合以及其製備及使用方法
HK40036124A (en) Methods of using dipivefrin
WO2014014150A1 (en) Pharmaceutical composition comprising antiviral neuraminidase inhibitor and permeation enhancer for enhanced oral bioavailability
HK40036124B (en) Methods of using dipivefrin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination